Premium
Bone marrow transplants for paroxysmal nocturnal haemoglobinuria
Author(s) -
Sašo Radovan,
Marsh Judith,
Čevreska Lidija,
Szer Jeffrey,
Gale Robert Peter,
Rowlings Philip,
Passweg Jakob,
Nugent Melodee,
Luzzatto Lucio,
Horowitz Mary,
GordonSmith Edward
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01195.x
Subject(s) - medicine , bone marrow , haemolysis , bone marrow failure , bone marrow transplant , surgery , aplastic anemia , bone marrow transplantation , stem cell , haematopoiesis , immunology , biology , genetics
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare clonal haematological disorder characterized by intravascular haemolysis and increased risk of thrombosis. PNH is associated with bone marrow failure syndromes including aplastic anaemia, myelodysplasia and leukaemia. Bone marrow transplants are sometimes used to treat PNH, but small series and reporting biases make assessment of transplant outcome difficult. The outcome of 57 consecutive allogeneic bone marrow transplants for PNH reported to the International Bone Marrow Transplant Registry (IBMTR) between 1978 and 1995 was analysed. The 2‐year probability of survival in 48 recipients of HLA‐identical sibling transplants was 56% (95% confidence interval 49–63%). Two recipients of identical twin transplants remain alive 8 and 12 years after treatment. One of seven recipients of alternative donor allogeneic transplants is alive 5 years after transplant. The most common causes of treatment failure were graft failure and infections. Our results indicate that bone marrow transplantion can restore normal bone marrow function in about 50% of PNH patients.